With an estimated prevalence of 8% to 16% worldwide, CKD has become a global public health issue. CKD is staged based on eGFR and other markers of kidney damage, such as albuminuria.[@bib1], [@bib2] More than 2 decades ago, genome-wide linkage analyses provided evidence that eGFR, serum creatinine, and creatinine clearance are heritable traits, with heritability estimates reaching from 19% to 46% after consideration of multiple risk factors for kidney function.[@bib3] During the past decade, at least 53 common loci were identified in GWAS for kidney function.[@bib4], [@bib5], [@bib6] Early identification of participants at high risk for future deterioration in kidney function is of importance, as it could enable early interventions to reduce progression to kidney failure or cardiovascular risk.[@bib7] However, the question of whether genetic markers may aid to improve prediction of future kidney function remains open.[@bib8] So far, one study of 26,000 participants from 8 population-based cohorts of European ancestry showed that most of the 16 SNPs tested associated or showed a tendency for association with incidence of CKD during a median follow-up time of 7 years.[@bib9] In addition, 2 studies created genetic risk scores (GRS) of either 16 or 53 SNPs identified in GWAS for creatinine-based eGFR, and used them to predict incidence of stage 3 CKD, but reported no significant improvements of the prediction models beyond the traditional clinical risk factors.[@bib10], [@bib11] On the contrary, recent results from the PREVEND study reported strong associations of a similar GRS with cross-sectional kidney outcomes (baseline eGFR and prevalent CKD), yet the association with CKD incidence diminished when the multivariate model was adjusted for baseline eGFR.[@bib12] Thus, the evidence if SNPs associated with cross-sectional kidney function may aid in predicting long-term kidney outcomes remains inconclusive. Therefore, in this study we aimed to investigate the joint effect of the 53 in GWAS identified genetic markers,[@bib4] combined into a genetic risk score (GRS~CKD~), on longitudinal kidney function in the prospective Malmö Diet and Cancer Study--Cardiovascular Cohort (MDCS-CC).

Methods {#sec1}
=======

Study Participants {#sec1.1}
------------------

For this study, we included participants from the Malmö Diet and Cancer Study (MDCS), a Swedish population-based cohort that has been described in detail elsewhere.[@bib13] In brief, during the baseline examination between 1991 and 1996, men and women born between 1923 and 1945, and 1923 and 1950, respectively, were invited to participate. The total participation rate was 40.8%. MDCS was approved by the ethics committee at Lund University (LU 51-90) and written informed consent was given by all the participants.

This study included individuals from the MDCS--Cardiovascular Cohort (MDCS-CC), which randomly selected 6103 participants of MDCS who underwent additional phenotyping, designed to study epidemiology of carotid artery disease, between 1991 and 1994. Between 2007 and 2012, this random sample was re-invited to a follow-up reexamination as described previously,[@bib14] and of the total of 4924 individuals who were invited (i.e., those who were alive and had not emigrated from Sweden), 3734 attended the follow-up reexamination.

When participants with missing data on baseline or follow-up eGFR or on any covariates, lack of DNA, or an eGFR at baseline of less than 60 mL/min per 1.73 m^2^ were excluded, 2301 participants were left for the analyses ([Supplementary Figure S1](#appsec1){ref-type="sec"}).

Measurements {#sec1.2}
------------

During the baseline examination, anthropometric measurements were taken by trained personnel, and all participants underwent a physical examination. BMI was calculated as weight/height^2^ (kg/m^2^) and SBP and diastolic blood pressure (DBP) were measured (mm Hg). Questions concerning social economic status, lifestyle factors, and medical history were assessed by a self-administrated questionnaire.[@bib13] Fasting blood samples were drawn and immediately frozen to −80°C and stored in a biological bank.[@bib15]

Plasma creatinine (μmol/l) was measured and analyzed with the Jaffé method, and traceable to the International Standardization with isotope dilution mass spectometry. Cystatin C was measured using a particle-enhanced immunonephelometric assay (N Latex Cystatin; Dade Behring, Deerfield, IL). The values of cystatin C were not standardized because they were analyzed before the introduction of the world calibrator in 2010. The reference value for the method was 0.53 to 0.95 mg/l. eGFR was calculated based on the previously reported CKD--Epidemiology Collaboration 2009 creatinine-based equation.[@bib16] A factor of 0.0113 was included to convert creatinine levels measured in μmol/l into mg/dl.

Outcome {#sec1.3}
-------

Incidence of CKD was defined as having an eGFR \<60 mL/min per 1.73 m^2^ at the follow-up reexamination.

Genotyping and Creation of the GRS {#sec1.4}
----------------------------------

For this study, we included 53 SNPs that were previously identified to be associated with kidney function in GWAS.[@bib4] Genotyping was performed using the Illumina (San Diego, CA) Human OmniExpress BeadChip v1, at the Broad Institute, Cambridge, MA. During the quality control procedure, individuals were filtered out if the call rate was less than 0.95, an inbreeding coefficient of \>3 SD away from mean was observed, discordance between inferred and reported gender occurred, duplicate samples were identified, unexpected high proportion of identity by descent sharing was observed, and if first- and second-degree relatives or deviation from the common population structure in the MDCS-CC (exceeding 8 sigma on the first 2 principal components) was observed. In addition, SNPs were filtered out if they were monomorphic or had a call rate of \<0.95, had an extreme deviation from the Hardy--Weinberg equilibrium (*P* \< 1 × 10^--07^), were missing in either cases or controls (*P* \<1 × 10^--07^ and minor allele frequency \> 0.01) and if an error in the plate assignment occurred (*P* \<1 × 10^--08^ and minor allele frequency \> 0.01).

A weighted genetic risk score (wGRS~CKD~) was constructed by summing the number of risk alleles (0, 1, or 2) of each of the 53 SNPs per participant weighted for their published regression coefficients.[@bib4] The allele frequencies of the 53 SNPs in MDCS-CC and further details are presented in supplementary material ([Supplementary Table S1](#appsec1){ref-type="sec"}A). In addition, we updated the GRS (GRS~CKD63~) with 10 additional SNPs recently identified by Gorski *et al.*[@bib17] Both a weighted and unweighted GRS~CKD63~ were constructed. This updated score included in total 63 SNPs and the details of the additional 10 SNPs are provided in the supplementary material ([Supplementary Table S1](#appsec1){ref-type="sec"}B). In addition, the study participants were categorized according to the wGRS~CKD~ into quartiles.

Statistics {#sec1.5}
----------

SPSS (version 21; IBM Corporation, Armonk, NY) and STATA version 13 (StataCorp LP, College Station, TX) were used for statistical analyses.

General linear regression was used to test the association between the wGRS~CKD~ and eGFR at baseline adjusted for age and sex, and eGFR at follow-up reexamination adjusted for age, sex, baseline eGFR, and follow-up time.

The relationship between the wGRS~CKD~ and CKD at the follow-up reexamination was tested using logistic regression adjusting for age, sex, baseline eGFR, and follow-up time (years), and for known risk factors for CKD at baseline, including BMI, SBP, fasting glucose, use of antihypertensive treatment (AHT), and smoking status.

*P* for trend across genotypes was calculated assuming an additive model (i.e., genotypes coded as 0, 1, or 2 risk alleles) using wGRS~CKD~ as a continuous variable in the regression models.

The Net Reclassification Improvement (NRI)[@bib18] was calculated using *nri* STATA command for the package idi from <http://personalpages.manchester.ac.uk/staff/mark.lunt>. The model discrimination was tested by calculating C-statistic using *roccomp* command in STATA for models using risk factors with and without the wGRS~CKD.~

All the presented *P* values are 2-sided, and *P* \< 0.05 was considered as significant.

Results {#sec2}
=======

Associations With Clinical Characteristics at Baseline {#sec2.1}
------------------------------------------------------

Most of the 2301 participants were women (58.2%) and were on average 56.0 (SD 5.6) years old at baseline. The mean baseline eGFR was 78.9 (range 60.2--129.2) mL/min per 1.73 m^2^ ([Table 1](#tbl1){ref-type="table"}). The maximum number of risk alleles in our population was 72 and the minimum was 40, and 71% of the population had 50 to 60 risk alleles. wGRS~CKD~ was strongly associated with a lower baseline eGFR (*P* = 6.5 × 10^--8^). Also the wGRS~CKD~ was significantly associated with baseline eGFR after Bonferroni correction for 53 tests (*P* \< 9.4 × 10^--4^); only a total 6 SNPs reached nominal significance (*P* \< 0.05) ([Table 2](#tbl2){ref-type="table"}). In addition, the wGRS~CKD~ associated with baseline creatinine (*P* = 9.6 × 10^--8^) and cystatin C (*P* = 0.001) levels, and albeit much weaker, also with height (*P* = 0.018) and diastolic blood pressure (DBP; *P* = 0.033) but not with further baseline characteristics ([Table 1](#tbl1){ref-type="table"}).Table 1Baseline characteristics of 2301 participants from the Malmö Diet and Cancer Study--Cardiovascular Cohort stratified by genetic risk score for CKD (wGRS~CKD~)*n*AllQuartiles of the wGRS~CKD~*P*-trend[a](#tbl1fna){ref-type="table-fn"}Mean (SD)Q1 (*n* = 575)Q2 (*n* = 575)Q3 (*n* = 575)Q4 (*n* = 575)Alleles, mean (range)230156 (40--72)50 (39--53)55 (53--56)58 (56--59)62 (59--72)--Male sex,[b](#tbl1fnb){ref-type="table-fn"}*n* (%)2301963 (41.8)246 (42.8)242 (42.1)230 (40.0)245 (42.5)0.783Age (yr)230156.0 (5.6)56.3 (5.7)55.8 (5.5)55.9 (5.6)55.9 (5.6)0.199Height (cm)2301169.5 (8.8)169.0 (8.5)169.5 (9.0)169.5 (9.0)169.6 (8.7)0.018Weight (kg)230173.1 (13.0)73.0 (12.4)73.1 (13.4)73.2 (12.6)73.0 (13.6)0.779BMI (kg/m^2^)230125.4 (3.6)25.5 (3.7)25.4 (3.8)25.4 (3.5)25.2 (3.6)0.245SBP (mm Hg)2301138.4 (17.8)139.6 (18.2)137.5 (17.8)138.5 (17.3)138.0 (17.6)0.389DBP (mm Hg)230186.0 (9.0)86.8 (9.0)85.7 (9.0)85.9 (8.7)85.5 (9.4)0.033Fasting glucose (mmol/l)23015.0 (1.1)5.1 (1.1)5.1 (1.0)5.00 (1.1)5.0 (1.0)0.398Cystatin C (mg/dl)21700.75 (0.12)0.74 (0.11)0.74 (0.12)0.76 (0.1)0.76 (0.1)0.001Creatinine (μmol/l)230182.3 (11.9)81.2 (11.9)81.6 (11.8)82.5 (11.8)83.9 (11.7)9.6 × 10^--8^eGFR at baseline (mL/min per 1.73 m^2^)230178.9 (11.4)80.1 (11.4)79.7 (11.4)78.4 (11.5)77.3 (10.9)6.5 × 10^--8^eGFR at follow-up[c](#tbl1fnc){ref-type="table-fn"} (mL/min per 1.73 m^2^)230171.71 (14.6)74.2 (13.7)72.1 (14.5)71.0 (15.4)69.6 (14.4)5.0 × 10^--10^AHT,[d](#tbl1fnd){ref-type="table-fn"}*n* (%)2301319 (13.9)91 (15.8)76 (13.2)88 (15.3)64 (11.2)0.077Current smoking,[d](#tbl1fnd){ref-type="table-fn"}*n* (%)2301533 (23.2)138 (24.0)136 (23.7)142 (24.7)117 (20.3)0.161[^1][^2][^3][^4][^5][^6]Table 2Kidney function based on eGFR at baseline and at the follow-up reexamination in relation to wGRS~CKD~ and the individual SNPs included in the genetic risk score for CKD (GRS~CKD~) in 2301 participants from the Malmö Diet and Cancer Study--Cardiovascular CohortSNP-IDCHRLocusRisk allele (RAF)eGFR at baseline examinationeGFR at follow-up reexaminationRisk for incidence of CKD at follow-up reexaminationBeta (SE)*P* value[a](#tbl2fna){ref-type="table-fn"}*P* value[a](#tbl2fna){ref-type="table-fn"}^,^[b](#tbl2fnb){ref-type="table-fn"}Beta (SE)*P* value[c](#tbl2fnc){ref-type="table-fn"}*P* value[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}OR (95% CI)*P* value[d](#tbl2fnd){ref-type="table-fn"}*P* value[b](#tbl2fnb){ref-type="table-fn"}^,^[d](#tbl2fnd){ref-type="table-fn"}wGRS~CKD~ per 1-SD increment−1.26 (0.22)5.3 e-09[e](#tbl2fne){ref-type="table-fn"}2.65 e09[e](#tbl2fne){ref-type="table-fn"}−1.27 (0.27)2.6 e-06[e](#tbl2fne){ref-type="table-fn"}1.3 e06[e](#tbl2fne){ref-type="table-fn"}1.25 (1.12--1.39)0.000097360.00004868[e](#tbl2fne){ref-type="table-fn"}rs18006151*CASP9*T (0.32)−0.62 (0.33)0.0630.0315−0.50 (0.41)0.2260.1131.16 (0.99--1.37)0.0740.037rs2677341*LASS2*T (0.80)−0.22 (0.38)0.5610.2805−0.14 (0.47)0.7610.38050.98 (0.81--1.18)0.8020.599rs121360631*SYPL2*G (0.33)−0.49 (0.33)0.1310.0655−0.23 (0.40)0.5560.2781.07 (0.91--1.26)0.4050.2025rs38506251*CACNA1S*G (0.87)−0.08 (0.46)0.8600.43−0.45 (0.57)0.4350.21751.07 (0.84--1.34)0.5920.296rs26363191*SDCCAG8*C (0.45)0.20 (0.30)0.5180.7410.00 (0.38)0.9990.50150.99 (0.85--1.15)0.8970.552rs8076242*DDX1*G (0.65)0.15 (0.32)0.6400.68−0.23 (0.40)0.5570.27851.08 (0.92--1.27)0.3500.175rs12603262*GCKR*C (0.64)−0.27 (0.32)0.3940.197−0.01 (0.39)0.9850.49250.92 (0.79--1.08)0.3090.846rs65468382*ALMS*A (0.76)−0.67 (0.36)0.0640.032−0.21 (0.45)0.6360.3181.00 (0.83--1.20)0.9950.4975rs10478912*CPS1*A (0.33)−0.57 (0.34)0.0970.0485−0.50 (0.43)0.2460.1231.07 (0.90--1.27)0.4370.2185rs27121842*IGFBP5*A (0.58)−0.52 (0.31)0.0950.04750.31 (0.39)0.4250.7881.02 (0.87--1.19)0.8420.421rs67590132*LRP2*A (0.51)0.54 (0.30)0.0760.620.03 (0.38)0.9370.5321.00 (0.86--1.17)0.9770.4885rs76443833*TFDP2*T (0.72)−0.70 (0.34)0.0390.01950.55 (0.42)0.1860.9070.93 (0.79--1.10)0.3840.808rs96820413*SKIL*T (0.88)−0.11 (0.48)0.8270.41350.03 (0.60)0.9560.5221.09 (0.85--1.40)0.4820.241rs105138013*ETV5*G (0.11)−0.49 (0.50)0.3220.161−0.38 (0.62)0.5420.2710.89 (0.69--1.14)0.3580.821rs98640313*WNT7A*T (0.82)0.20 (0.40)0.6240.688−0.49 (0.50)0.3270.16351.08 (0.88--1.33)0.4580.229rs173197214*SHROOM3*A (0.45)−0.32 (0.31)0.2980.149−0.23 (0.38)0.5450.27250.96 (0.82--1.11)0.5660.717rs28664134*NFKB1*G (0.50)0.40 (0.30)0.1860.907−0.33 (0.38)0.3860.1930.90 (0.77--1.05)0.1810.910rs119599285*DAB2*A (0.43)0.24 (0.31)0.4360.782−0.56 (0.38)0.1400.071.00 (0.86--1.17)0.9740.487rs64200945*SLC34A1*G (0.31)−0.51 (0.33)0.1170.0585−0.54 (0.40)0.1820.0910.98 (0.83--1.15)0.7780.611rs8818586*VEGFA*A (0.71)−0.77 (0.34)0.0210.01050.23 (0.42)0.5870.7070.98 (0.83--1.17)0.8510.5745rs3160096*SLC22A2*C (0.90)−0.94 (0.50)0.0630.0315−0.91 (0.63)0.1460.0731.21 (0.92--1.58)0.1740.087rs77590016*ZNF204*A (0.77)0.31 (0.36)0.3900.805−0.08 (0.45)0.8580.4291.07 (0.89--1.29)0.4410.2205rs117659867*TMEM60*T (0.26)−0.55 (0.35)0.1110.0555−0.39 (0.43)0.3640.1821.19 (1.00--1.41)0.0440.022rs78057477*PRKAG2*A (0.26)−0.30 (0.35)0.4010.2005−0.81 (0.44)0.0660.0331.10 (0.92--1.30)0.3060.153rs102771157*UNCX*A (0.24)−0.46 (0.36)0.2070.1035−0.36 (0.45)0.4200.211.08 (0.90--1.30)0.3830.1915rs77850657*KBTBD2*C (0.61)0.24 (0.32)0.4490.7760.15 (0.39)0.7110.6450.94 (0.80--1.11)0.4730.764rs64596807*RNF32*T (0.75)−0.24 (0.36)0.4990.24950.04 (0.44)0.9320.5340.95 (0.79--1.13)0.5490.720rs69994848*STC1*A (0.46)−0.35 (0.31)0.2550.12750.14 (0.38)0.7070.6471.04 (0.89--1.22)0.5910.2955rs15567519*PIP5K1B*G (0.39)−0.25 (0.32)0.4250.2125−0.51 (0.39)0.1950.09751.03 (0.88--1.20)0.7320.366rs104426110*WDR37*T (0.07)0.47 (0.60)0.4350.783−0.27 (0.75)0.7160.3581.08 (0.79--1.46)0.6370.3185rs1099486010*A1CF*C (0.81)−0.17 (0.39)0.6620.331−0.26 (0.49)0.5960.2981.37 (1.11--1.70)0.0030.0015rs392558411*MPPED2*T (0.55)−0.21 (0.31)0.5010.25050.23 (0.39)0.5590.7210.97 (0.83--1.13)0.6980.651rs16315811*KCNQ1*A (0.17)0.32 (0.40)0.4180.7910.09 (0.50)0.8520.5471.03 (0.84--1.25)0.8070.4035rs401419511*AP5B1*G (0.36)−0.38 (0.32)0.2380.119−0.42 (0.40)0.2940.1471.03 (0.87--1.21)0.7390.3695rs1077402112*SLC6A13*T (0.67)−1.13 (0.33)0.00058[e](#tbl2fne){ref-type="table-fn"}0.00029[e](#tbl2fne){ref-type="table-fn"}0.18 (0.41)0.6570.6720.95 (0.80--1.12)0.5440.728rs1049196712*TSPAN9*A (0.09)−0.16 (0.52)0.7560.378−0.56 (0.65)0.3830.19151.03 (0.80--1.33)0.8020.401rs795677312*PTPRO*T (0.82)−0.43 (0.40)0.2780.1390.19 (0.49)0.6970.6521.06 (0.86--1.29)0.5920.296rs110676612*INHBC*C (0.73)−0.22 (0.34)0.5150.25750.02 (0.42)0.9680.5161.08 (0.91--1.28)0.3810.1905rs62627713*DACH1*A (0.60)−0.26 (0.31)0.4120.2060.53 (0.39)0.1750.9130.98 (0.84--1.15)0.8020.599rs803219515*INO80*A (0.39)−0.01 (0.32)0.7550.3775−0.73 (0.39)0.0630.03151.15 (0.98--1.35)0.0770.0385rs246785315*GATM*G (0.39)−0.64 (0.31)0.0410.0205−0.16 (0.39)0.6850.34251.12 (0.96--1.31)0.1550.0775rs49156715*WDR72*A (0.76)−0.30 (0.36)0.3920.196−1.15 (0.44)0.0090.00451.24 (1.03--1.49)0.0240.012rs139412515*UBE2Q2*A (0.33)−0.50 (0.33)0.1310.0655−0.07 (0.41)0.8690.43450.97 (0.82--1.14)0.6980.651rs1291770716*UMOD*G (0.82)−0.91 (0.41)0.0290.0145−2.17 (0.51)0.000019[e](#tbl2fne){ref-type="table-fn"}0.0000095[e](#tbl2fne){ref-type="table-fn"}1.59 (1.27--1.98)0.000047[e](#tbl2fne){ref-type="table-fn"}0.0000235[e](#tbl2fne){ref-type="table-fn"}rs16474916*DPEP1*G (0.42)−0.58 (0.31)0.0650.03250.22 (0.39)0.5620.7190.96 (0.82--1.13)0.6330.684rs89468017*SLC47A1*A (0.39)−0.31 (0.31)0.3230.16150.31 (0.39)0.4210.7901.03 (0.88--1.20)0.7160.358rs722187517*CDK12/ FBXL20*G (0.76)0.12 (0.35)0.7210.640−1.11 (0.43)0.0100.0051.22 (1.02--1.46)0.0320.016rs990527417*BCAS3*T (0.16)0.39 (0.44)0.3710.815−0.35 (0.54)0.5170.25851.07 (0.86--1.33)0.5610.2805rs809118018*NFATC1*A (0.56)−0.63 (0.31)0.0430.0215−0.16 (0.38)0.6810.34050.98 (0.84--1.14)0.7570.622rs1246087619*SLC7A9*T (0.66)−0.26 (0.33)0.4280.214−0.25 (0.40)0.5350.26751.00 (0.85--1.18)0.9720.486rs180715719*SIPA1L3*T (0.16)−0.05 (0.43)0.9030.45150.60 (0.53)0.2580.8710.80 (0.64--1.00)0.0500.975rs227368420*TP53INP2*G (0.49)−0.57 (0.31)0.0640.032−0.78 (0.38)0.0420.0211.12 (0.96--1.31)0.1600.08rs1721670720*BCAS1*T (0.80)0.23 (0.38)0.5480.726−0.76 (0.48)0.1100.0551.33 (1.09--1.63)0.00560.0028[^7][^8][^9][^10][^11][^12][^13]

Longitudinal Changes in Kidney Function From Baseline to Follow-up Reexamination and Incidence of CKD at the Follow-up Reexamination {#sec2.2}
------------------------------------------------------------------------------------------------------------------------------------

The mean eGFR at follow-up was 71.7 (range 6.2--114.8) mL/min per 1.73 m^2^ and the wGRS~CKD~ was significantly associated with eGFR at follow-up reexamination after adjusting for age, sex, baseline eGFR, and follow-up time (*P* = 5.0 × 10^--10^) ([Table 1](#tbl1){ref-type="table"}). During a mean follow-up time of 16.6 (13.3--20.2) years there were in total 453 (19.7%) participants whose eGFR decreased to below 60 mL/min per 1.73 m^2^ by the follow-up reexamination. Baseline characteristics of participants with and without incident CKD are shown in [Supplementary Table S3](#appsec1){ref-type="sec"}. We observed a significantly increased CKD incidence at follow-up reexamination with increasing wGRS~CKD~ (*P* = 0.00029 per 1 SD increment in the wGRS~CKD~). There was a 22% increased risk for incident CKD (OR: 1.22; 95% CI: 1.10--1.37) after adjusting for age, sex, baseline, eGFR, and follow-up time. When adjusting for further baseline risk factors, BMI, fasting glucose, SBP, antihypertensive treatment (AHT), and smoking status, the wGRS~CKD~ remained significantly associated with CKD at follow-up (OR: 1.25; 95% CI: 1.12--1.39 per 1 SD increment in the wGRS~CKD~) ([Table 2](#tbl2){ref-type="table"}). We found no evidence that including the covariates would markedly affect the associations between the wGRS~CKD~ and kidney function ([Supplementary Table S4](#appsec1){ref-type="sec"}). Participants within the highest quartile of risk alleles had a 97% increased risk for incident CKD compared with those in the lowest quartile (Q1 vs. Q4, OR: 1.97; 95 % CI: 1.43--2.70; [Figure 1](#fig1){ref-type="fig"}). The highest risk increase, 34%, was observed for participants in Q2 compared with those with the lowest number of risk alleles (Q1). Between the intermediate quartiles there was a higher risk of 33% for participants in Q3 compared with those in Q2. Participants with the highest number of risk alleles (Q4) had an additional 30% higher risk compared with those in Q3 ([Figure 1](#fig1){ref-type="fig"}); however, adding the wGRS~CKD~ to the model with clinical risk factors did not improve the discrimination between participants with and without incident CKD at follow-up reexamination (area under the curve \[AUC\]~clinicalRiskfactors~ vs. AUC~clinicalRiskfactors+GRS~ 0.726 vs. 0.731; *P* = 0.12) ([Supplementary Figure S3](#appsec1){ref-type="sec"}). The fit for both models was adequate (Hosmer-Lemenshow for both *P* \> 0.05). However, the NRI index was significantly improved, as adding the wGRS~CKD~ to the risk model reclassified 21.3% of the participants into the correct risk direction (95% CI: 21.24--21.44; *P* \< 0.0001) ([Supplementary Figure S4](#appsec1){ref-type="sec"}). When the wGRS~CKD~ was added to the model including clinical risk factors, most of both the cases (56.07%) as well as noncases (54.60%) were reclassified into the correct risk direction.Figure 1Incidence of chronic kidney disease (CKD) according to quartiles of the genetic risk score for CKD (wGRS~CKD~) in 2301 participants of the Malmö Diet and Cancer Study--Cardiovascular Cohort after an average follow-up time of 16 years. The figure shows odds ratios (ORs) and 95% confidence intervals (CIs) for having an estimated glomerular filtration rate (eGFR) of \<60 mL/min per 1.73 m^2^ obtained from logistic regression analysis adjusted for age, sex, baseline levels of eGFR, fasting glucose, body mass index, systolic blood pressure, smoking status (current, former, or never smokers), use of antihypertensive drugs (yes/no), and follow-up time. The eGFR was calculated according to CKD--Epidemiology Collaboration 2009 creatinine equation,[@bib16] and all 2301 study participants had a baseline eGFR of ≥60 mL/min per 1.73 m^2^. Q1 = lowest quartile as reference was set to 1. The OR and respective 95% CI for each quartile are displayed above each column. Compared with the reference quartile Q1, the ORs for Q2, Q3, and Q4 were as follows: Q2 OR: 1.34, 95% CI: 0.96--1.87, *P* = 0.081; Q3 OR: 1.67, 95% CI: 1.21--2.30, *P* = 0.001; Q4 OR: 1.97, 95% CI: 1.43--2.70, *P* = 0.00003 in the multivariate adjusted model.

Similar results were observed when we used the unweighted GRS~CKD~ ([Supplementary Figure S2](#appsec1){ref-type="sec"} and [Supplementary Table S4](#appsec1){ref-type="sec"})~.~

An Updated Score Including 63 SNPs Cross-sectionally Associated With eGFR {#sec2.3}
-------------------------------------------------------------------------

Recently, Gorski *et al.*[@bib17] discovered 10 additional loci that associated with eGFRcrea at *P* \< 5 × 10^--8^. In MDCS-CC, the mean number of risk alleles for GRS~CKD63~ was 65 (SD 5; range 51--80). The associations between GRS~CKD63~ and baseline eGFR, eGFR at follow-up, and incidence of CKD were comparable to those with GRS~CKD53~, for both weighted and unweighted GRSs ([Supplementary Table S3](#appsec1){ref-type="sec"} and [Supplementary Table S4](#appsec1){ref-type="sec"}).

Discussion {#sec3}
==========

After the mean follow-up time of 16.6 years, we observed a direct relationship between higher wGRS~CKD~ and increased CKD incidence in our Swedish population-based cohort, whereby the increase per 1-SD increment associated with a 27% increased risk, taking into account established risk factors for CKD. In our population, the highest number of risk alleles was 72 (of 106 possible) and lowest 40 (of 0 possible), and most of the participants carried 50 to 60 risk alleles; however, adding the wGRS~CKD~ to a risk model with clinical risk factors did not improve the discriminatory effect of the prediction model to differentiate CKD cases from non-CKD cases. Yet, including the wGRS~CKD~ in the risk model led to a significantly improved NRI index of 21.3%.

The genetic markers included in the GRS~CDK~ have previously been discovered in GWAS,[@bib4] and earlier, Ma *et al.*[@bib10] reported association between the same GRS of 53 SNPs and incidence of CKD stage 3 in the Framingham Heart Study. In fact, they observed similar results compared with our study, with a 37% increased CKD incidence per 10 risk alleles.[@bib10] Compared with our study, they had a somewhat higher number of study participants (2698 vs. 2301) but fewer incident cases (292 vs. 453) and a shorter follow-up time (11 vs. 16 years). In addition, the participants were of similar age (57.6 vs. 56.0 years), had somewhat higher BMI (27.5 vs. 25.4 kg/m^2^), but higher eGFR (92.3 vs. 78.9 mL/min per 1.73 m^2^) at baseline, which may explain the slightly higher risk increase in our study. The C-statistics were not improved in either study after adding the GRS to the model with the traditional risk factors. Yet, it must be kept in mind that the effect on the change in the AUC in the receiver operating characteristics analysis depends not only on the predictive ability of the "traditional risk model" and the strength of the new predictor (here the GRS~CKD~), but also on the potential correlation between them, and thus C-statistics often may be a rather insensitive measure.[@bib19], [@bib20] Nonetheless, by NRI analysis we observed that adding the GRS~CKD~ to the risk model led to a significant improvement, indicating potential value of the wGRS~CKD~ in risk classification, whereas such analyses were not reported in the Framingham Heart Study.[@bib10] In contrast to MDCS-CC, Thio *et al.*[@bib12] reported that association between the GRS and CKD incidence diminished when the multivariate model was adjusted for baseline eGFR. We think that this could at least partly be explained by the younger age, shorter follow-up time, higher eGFR, and lower number of cases, and thus lower statistical power in the PREVEND study as compared with our study (mean age 49 vs. 56 years, follow-up 11 vs. 16 years, baseline eGFR 96 vs. 79 mL/min per 1.73 m^2^, and number of incident cases 154 vs. 453, respectively).[@bib12]

Obviously, more studies are needed to estimate the value of genetic prediction of future kidney function, both in other population-based studies as well as among individuals at high risk for CKD, such as patients with hypertension or type 2 diabetes.

The genetic variants included in our GRS~CKD~ were initially identified in cross-sectional analyses of \>130,000 individuals from 49 studies and replicated in up to 42,000 additional individuals.[@bib4] Before our study, the question of which genetic variants associate with longitudinal decline of kidney function was recently raised in a GWAS including 63,558 individuals.[@bib21] However, only 1 locus, the rs12917707 in the gene encoding uromodulin (*UMOD*), was identified genome-wide significantly associated with a change in eGFR.[@bib21] The *UMOD* variant was already previously found to be associated with eGFR in the cross-sectional GWAS[@bib4] and was thus included in our GRS~CKD~. Indeed, of all the individual SNPs in our study, the *UMOD* SNP clearly provided the strongest association with CKD incidence, with 59% increased risk per risk allele (1.59 \[1.27--1.98\], *P* = 0.000047). Uromodulin is the most abundant protein excreted in the normal urine and is exclusively expressed in the thick ascending limb of the loop of Henle. The importance of *UMOD* in renal diseases was first fully appreciated when rare mutations of *UMOD* were discovered in a group of very rare autosomal-dominant tubulointerstitial renal diseases approximately 15 years ago (reviewed in Scolari *et al.*[@bib22]). The rs12917707 was recently reported in association with urinary uromodulin levels,[@bib23] and serum uromodulin levels were inversely associated with the development of CKD.[@bib24] Thus, both monogenic mutations and common variants in *UMOD* seem to have causal implications in the development of kidney diseases.

Even if there was no benefit in distinguishing CKD cases from non-CKD cases when the wGRS~CKD~ was added to a model including clinical risk factors (*P* value Δ AUC *P* = 0.12), it seems noteworthy that the results from the cNRI analysis show an improvement of 6.07% for CKD cases being correctly classified and likewise most participants without CKD at follow-up (54.60%) are correctly reclassified into lower risk. This shows that knowing the individual genetic risk may be of importance for those at increased risk, as it could allow them to act on this already earlier by primary regimens, such as lifestyle changes.

The heritability of eGFR has been estimated to be between 36% and 75%[@bib25], [@bib26] and the 53 SNP variants included in our GRS~CKD~ have been estimated to explain approximately 3.2% of the variance of eGFR.[@bib4] All these SNPs are common, with minor allele frequencies above 5% and discovery of less frequent variants with higher effect sizes could potentially explain a greater variance in eGFR[@bib10] and improve prediction of future kidney function. Toward this direction, a very recent study identified 10 novel genome-wide significant loci in a meta-analysis of GWAS cohorts including more than 110,000 adults using 1000 Genome imputed genotypes, which enhanced the coverage of the genomic variation.[@bib17] Nonetheless, all but 1 of the identified 10 novel variants were common and the variance of eGFR that was explained when added together with the earlier 53 variants was only slightly increased, yet remained less than 4%.[@bib17]

Our study has some limitations that deserve clarification. The outcome in our study was incidence of CKD, defined as an eGFR \<60 mL/min per 1.73 m^2^ at the follow-up reexamination, which does not fulfill the current Kidney Disease Improving Global Outcomes 2012 CKD guidelines[@bib27] that require an eGFR \<60 mL/min per 1.73 m^2^ for a duration of \>3 months for CKD diagnosis. We regret that, both at the baseline and the follow-up reexamination of our study, only one measurement of creatinine was performed. It is inarguable that more time points of creatinine measurement had been preferred, yet the long mean follow-up time of more than 16 years may increase the confidence in assessing the progression to CKD.[@bib27] Further, we did not have information on albuminuria at baseline, which would have been desirable, as it is a key biomarker in CKD risk assessment. However, we adjusted our analyses for many potential risk factors, including baseline eGFR, and this did not majorly influence the results.

Our study also has some strengths. First, it was conducted in an apparently healthy middle-aged Swedish population, making the findings generalizable to the general population of European ancestry. Second, our study had a long follow-up and therefore a reasonable number of incident CKD cases. Third, the risk for reverse causation was minimized given the prospective design and the fact that the exposure was the genetic make-up of the participants.

Conclusion {#sec4}
==========

In the prospective MDCS-CC, we observed that the wGRS~CDK~ of 53 genetic markers, previously associated with creatinine-based eGFR, associated with a significantly increased incidence of CKD. Although the wGRS~CKD~ did not improve the C-statistics beyond the traditional clinical risk factors, it aided in reclassification of individuals into the correct risk direction.
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**Table S1.** Genetic variants included in the GRS~CKD~**.**

**Table S2.** Kidney function based on eGFR at baseline and at the follow-up reexamination in relation to the GRS~CKD~ and the individual SNPs included in the genetic risk score for CKD (GRS~CKD~), including 63 SNPs in 2298 participants from the Malmö Diet and Cancer Study--Cardiovascular Cohort.

**Table S3.** Baseline characteristics among incident CKD and non-incident CKD cases in the MDCS-CC.

**Table S4.** Associations between the 4 GRSs and kidney function in the MDCS-CC.

**Figure S1.** Participants of the Malmö Diet and Cancer Study included in the longitudinal association analyses for the GRS~CKD~ and kidney function.

**Figure S2.** Genetic risk score and baseline eGFR in the Malmö Diet and Cancer Study. (A) The histogram represents the frequency among 4241 participants through the number of CKD risk alleles. Further, the predicted values of the baseline eGFR resulting from a crude unadjusted linear regression plotted across the genetic risk score are shown. *n* = 4241 refers to all participants in the dataset with data on eGFR at baseline and GRS available. The mean number of SNPs per participant was 56.5 (range: 42--71) and the genetic risk score (GRS) had *r*[@bib2] of 1.42%. (B) The histogram represents the frequency among 2301 participants through the number of CKD risk alleles. Further, the predicted values of the baseline eGFR resulting from a crude nonadjusted linear regression plotted across the genetic risk score are shown. *n* = 2301 refers to all participants in the dataset with data on eGFR at baseline, GRS, eGFR at follow-up reexamination, and covariates available. The mean number of SNPs per participant was 56.4 (range: 42--71) and the GRS had *r*^2^ of 0.97%.

**Figure S3.** Receiver operating characteristics (ROC) curve. ROC shown in blue resulting from predicted values from logistic regression adjusted for age, sex, FU-time, eGFR at baseline, BMI, SBP, AHT, fasting glucose, and smoking. ROC shown in red resulting from predicted values from logistic regression adjusted for age, sex, FU-time, eGFR at baseline, BMI, SBP, AHT, fasting glucose, smoking, and wGRS~CKD.~

**Figure S4.** Continuous NRI scatter plots for (A) CKD cases and (B) non-CKD cases at follow-up. The predicted probabilities from the clinical model + wGRS is given on the *y*-axis and the predicted probabilities from the clinical model on the *x*-axis. Predicted probabilities have been calculated for logistic regression models in (A) CKD cases and (B) non-CKD cases adjusted for age, sex, FU-time, eGFR at baseline, BMI, SBP, AHT, fasting glucose, and smoking (clinical model), and age, sex, FU-time, eGFR at baseline, BMI, SBP, AHT, fasting glucose, smoking, and wGRS~CKD~ (clinical model+wGRS), respectively.

[^1]: AHT, antihypertensive treatment; BMI, body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.

[^2]: Data are shown as mean (SD) for continuous variables or *n* (%) for categorical variables.

[^3]: *P* value from a sex- and age-adjusted linear regression model.

[^4]: *P* value for the categorical variable from an age-adjusted logistic regression.

[^5]: *P* value from a sex-, age-, baseline eGFR--, and follow-up time--adjusted linear regression model. eGFR was calculated according to CKD--Epidemiology Collaboration 2009 creatinine equation[@bib16] and all 2301 study participants had baseline eGFR of ≥60 mL/min per 1.73 m^2^.

[^6]: *P* value for the categorical variables from a sex- and age-adjusted logistic regression.

[^7]: AHT, antihypertensive treatment; BMI, body mass index; CHR, chromosome; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; OR, odds ratio; RAF, risk allele frequency; SBP, systolic blood pressure; SNP, single nucleotide polymorphism; wGRS~CKD~, genetic risk score weighted by the effect size.

[^8]: eGFR calculated according to CKD--Epidemiology Collaboration 2009 creatinine equation[@bib16] and all 2301 study participants had baseline eGFR of ≥60 mL/min per 1.73 m^2^.

[^9]: Adjusted for age and sex.

[^10]: One-sided *P* value.

[^11]: Adjusted for age, sex, baseline eGFR, and follow-up time.

[^12]: Adjusted for age, sex, baseline eGFR, fasting glucose, BMI, SBP, AHT, smoking status, and follow-up time.

[^13]: *P* \< 9.4 × 10^--4^ (Bonferroni corrected for 53 SNPs).
